AstraZeneca shareholders to change their tune when money rolls in
Your support helps us to tell the story
From reproductive rights to climate change to Big Tech, The Independent is on the ground when the story is developing. Whether it's investigating the financials of Elon Musk's pro-Trump PAC or producing our latest documentary, 'The A Word', which shines a light on the American women fighting for reproductive rights, we know how important it is to parse out the facts from the messaging.
At such a critical moment in US history, we need reporters on the ground. Your donation allows us to keep sending journalists to speak to both sides of the story.
The Independent is trusted by Americans across the entire political spectrum. And unlike many other quality news outlets, we choose not to lock Americans out of our reporting and analysis with paywalls. We believe quality journalism should be available to everyone, paid for by those who can afford it.
Your support makes all the difference.Outlook Big shareholders in AstraZeneca have been less than effusive about the bid.
Some, like Aberdeen's Martin Gilbert, express reservations about the potential long-term impact on Britain's science base. Others, like Neil Woodford, fret about the effect on the combined companies' value a few years hence, saying they prefer the current AstraZeneca management to be left alone. More still, like Swedish giant Investor AB, simply think it undervalues the business.
But the big shareholders' trading patterns suggest most are licking their collective lips for the inevitable moment Pfizer significantly ups its offer. That's why they've been spending billions of pounds in recent days and weeks increasing their stakes in AstraZeneca.
A quick squint at the share register shows Mr Gilbert's own fund managers seem less squeamish than him about the deal, pumping up Aberdeen's stake last week by £511m. BlackRock and Axa likewise have been big buyers. But wiliest money-runner so far has to be JPMorgan Chase, which bought five million AstraZeneca shares in March, bringing its holdings up to nearly 14 million and giving it a paper profit of nearly £50m.
When a bid comes in north of £55 a share, expect investors' protesting voices quietly to disappear.
Join our commenting forum
Join thought-provoking conversations, follow other Independent readers and see their replies
Comments